Literature DB >> 22771544

Methylated N-(4-N,N-dimethylaminobenzyl) chitosan coated liposomes for oral protein drug delivery.

Jariya Kowapradit1, Auayporn Apirakaramwong, Tanasait Ngawhirunpat, Theerasak Rojanarata, Warayuth Sajomsang, Praneet Opanasopit.   

Abstract

In the present study, methylated N-(4-N,N-dimethylaminobenzyl) chitosan (TM(56)Bz(42)CS) was synthesised and investigated for oral protein drug delivery by combining it with liposomes entrapped with fluorescein isothiocyanate-conjugated bovine serum albumin (FITC-BSA), a model protein. Liposomes (LPs) composed of 10:2 molar ratios of egg yolk phosphatidylcholine (EPC) and sodium oleate (NaO) were prepared by a thin film hydration method and coated with TM(56)Bz(42)CS. BSA-loaded, TM(56)Bz(42)CS-coated liposomes (TM(56)Bz(42)CS-coated FITC-BSA-LP) were evaluated for their protein transport efficiencies and cytotoxicities in Caco-2 cells. Moreover, the in vitro stabilities of the TM(56)Bz(42)CS-coated LP-BSA were determined by examining the degradation of the protein in simulated intestinal fluid containing 1% w/v pancreatin porcine pancreas. The mean particle size and zeta-potential of the TM(56)Bz(42)CS-coated LP-BSA were 128 ± 15 nm and 5.38 ± 1.66 mV, respectively. Additionally, the initial FITC-BSA to lipid ratio (2.5% w/w) showed the highest entrapment efficiency percentage (50.13%) and FITC-BSA content (8.08 mg/g of lipid) overall. The results of the FITC-BSA transport showed that the TM(56)Bz(42)CS-coated FITC-BSA-LP enhanced protein permeability across the Caco-2 cell monolayers with low cytotoxicity. In addition, these liposomes protected against protein degradation in pancreatin. Our studies demonstrated that TM(56)Bz(42)CS-coated liposomes have the potential to be used in oral protein drug delivery methods.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22771544     DOI: 10.1016/j.ejps.2012.06.020

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  6 in total

1.  Effects of Cisplatin-Loaded Niosomal Nanoparticleson BT-20 Human Breast Carcinoma Cells

Authors:  Leila Kanaani; Iraj Javadi; Meysam Ebrahimifar; Hasan Ebrahimi Shahmabadi; Azim Akbarzadeh Khiyav; Torkan Mehrdiba
Journal:  Asian Pac J Cancer Prev       Date:  2017-02-01

2.  Development of acid-resistant alginate/trimethyl chitosan nanoparticles containing cationic β-cyclodextrin polymers for insulin oral delivery.

Authors:  Maryam Mansourpour; Reza Mahjub; Mohsen Amini; Seyed Naser Ostad; Elnaz Sadat Shamsa; Morteza Rafiee-Tehrani; Farid Abedin Dorkoosh
Journal:  AAPS PharmSciTech       Date:  2015-01-22       Impact factor: 3.246

Review 3.  Micro and nanoscale technologies in oral drug delivery.

Authors:  Samad Ahadian; Joel A Finbloom; Mohammad Mofidfar; Sibel Emir Diltemiz; Fatemeh Nasrollahi; Elham Davoodi; Vahid Hosseini; Ioanna Mylonaki; Sivakoti Sangabathuni; Hossein Montazerian; Kirsten Fetah; Rohollah Nasiri; Mehmet Remzi Dokmeci; Molly M Stevens; Tejal A Desai; Ali Khademhosseini
Journal:  Adv Drug Deliv Rev       Date:  2020-07-22       Impact factor: 15.470

Review 4.  Multifunctional oral delivery systems for enhanced bioavailability of therapeutic peptides/proteins.

Authors:  Ying Han; Zhonggao Gao; Liqing Chen; Lin Kang; Wei Huang; Mingji Jin; Qiming Wang; You Han Bae
Journal:  Acta Pharm Sin B       Date:  2019-01-10       Impact factor: 11.413

5.  Fate of paclitaxel lipid nanocapsules in intestinal mucus in view of their oral delivery.

Authors:  Anne-Claire Groo; Patrick Saulnier; Jean-Christophe Gimel; Julien Gravier; Caroline Ailhas; Jean-Pierre Benoit; Frederic Lagarce
Journal:  Int J Nanomedicine       Date:  2013-11-07

6.  Effect of different types of surfactants on the physical properties and stability of carvedilol nano-niosomes.

Authors:  Somayeh Taymouri; Jaleh Varshosaz
Journal:  Adv Biomed Res       Date:  2016-03-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.